Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Advanced NSCLC
NCT02574078Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (10 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Progression-Free Survival at 48 months, Overall Survival at 60 months and 1 more. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02574078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02574078.